Escherichia coli for producing L-valine and application thereof

By genetically modifying E. coli K-12MG1655, enhancing the activity of related genes and knocking out specific genes, the problems of feedback inhibition and low transport efficiency of L-valine synthesis in E. coli are solved, and efficient production of L-valine is achieved The acid method simplifies the separation and purification process.

CN118931932APending Publication Date: 2024-11-12JIANGNAN UNIV
View PDF 0 Cites 3 Cited by

Patent Information

Application Number
CN202411020224.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Due to feedback inhibition, insufficient supply of precursor substances, low transport protein capacity and low cofactor circulation efficiency, L-valine cannot be synthesized in large quantities, and existing improvement measures are available. Inadequate feedback suppression effect.

Method used

By genetically modified E. coli K-12MG1655, the activity of genes such as acetyllactate synthase subunits I, II, III, II carboxylic acid reducing isomerase, II dehydrase, branched chain amino acid amino acid transaminase, transporter, etc. was enhanced, and knocked down Remove valine-pyruvate aminotransferase, lactate dehydrogenase and regulatory RNA genes to improve the feedback inhibition and transport system efficiency of L-valine.

Benefits of technology

The production of L-valine using glucose as substrate is achieved, which eliminates feedback inhibition, improves yield, enhances the efficiency of the decomposition pathway and product transportation system, simplifies the downstream separation and purification steps, and has good production potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004967000730000051
    Figure BDA0004967000730000051
  • Figure BDA0004967000730000061
    Figure BDA0004967000730000061
  • Figure BDA0004967000730000071
    Figure BDA0004967000730000071
Patent Text Reader

Abstract

According to the escherichia coli, escherichia coli K-12MG1655 is regulated and modified through a metabolic engineering means, so that the escherichia coli K-12MG1655 achieves de novo synthesis and accumulation of L-valine, L-valine is produced through fermentation with glucose as a substrate, a feedback inhibition pathway is relieved, and the L-valine can be produced through fermentation. The yield is improved, and good prospects and production potential are achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of biotechnology, and specifically relates to an Escherichia coli producing L-valine and its application Background Art

[0002] L-Valine (L-Val), molecular formula C5H 11 NO2, with a molecular weight of 117.15, is an essential amino acid that cannot be synthesized in mammals. Isoleucine and isoleucine are collectively referred to as branched-chain amino acids (BCAAs). It is widely used in the pharmaceutical, nutritional supplement and animal feed industries. Its biological function is mainly reflected in its role as one of the limiting amino acids, which can inhibit the degradation of tissue proteins and improve the quality of livestock and poultry carcasses; and it affects the strength of immune function by affecting the development of immune organs and the synthesis of immunoglobulins. With the rapid development of anticancer drug preparations, amino acid infusion preparations and sweet dipeptides, the demand for raw amino acids is increasing, and the market demand is increasing. my country is the main producer, consumer and exporter of L-valine in the world. It is of great significance to achieve efficient and green synthesis of L-valine, and it also has great application value and market demand.

[0003] At present, there are four main methods for producing L-valine, namely protein hydrolysis and extraction, chemical synthesis, enzyme catalysis and bio-fermentation. The protein hydrolysis and extraction method uses animal blood meal, silkworm pupae and hair as raw materials for hydrolysis, and extracts valine from the hydrolyzate, but there are disadvantages such as low proportion of valine in the hydrolyzate and difficulty in separating valine of different configurations. Although it can be separated by ion exchange, for large-scale industrial production, it is necessary to improve the system separation effect of ion exchange resin and the separation efficiency of products, and the separation cost is high, so this method is rarely used in production at present. The chemical synthesis method mainly uses isobutyraldehyde as raw material, reacts with ammonia to generate aminoisobutanol, and then synthesizes aminoisobutyronitrile with hydrocyanic acid, and then hydrolyzes to obtain DL-valine, which is further separated by enzymatic or chemical methods to obtain optically active valine. There are many steps and the reaction is complicated, so it cannot be applied on a large scale. The enzymatic method uses mixed DL-norvaline as a substrate to generate L-valine through an enzymatic reaction. The disadvantages are high raw material costs, lack of efficient catalytic enzymes, and low enzyme reuse rate. Currently, biofermentation has become the main method for L-valine. The de novo pathway can use cheap carbon sources (glucose, sucrose, etc.) as substrates for L-valine synthesis.

[0004] Microbial fermentation has sustainable and environmentally friendly socio-economic benefits. Escherichia coli is a base strain with simple gene editing, clear genetic metabolic pathways and short fermentation cycle. It is suitable for L-valine production in the pharmaceutical, nutritional supplement and animal feed industries because its L-valine does not contain allergens. However, the metabolic pathway for L-valine synthesis in Escherichia coli cannot be synthesized in large quantities due to feedback inhibition of L-valine, insufficient supply of precursor substances, low transporter capacity and low cofactor circulation efficiency. 10 mg / L has reached the threshold of feedback inhibition. Existing synthesis methods mainly focus on strengthening the synthetic metabolic pathway, improving the efficiency of the transport system (reducing the efficiency of the transport protein), optimizing the supply of cofactors, and improving the glucose uptake capacity. The closest solution is to introduce the acetolactate synthase gene alsS from Bacillus subtilis 168 into the Escherichia coli W3110 strain to relieve the feedback inhibition of Escherichia coli's own L-valine on acetolactate synthase, a key rate-limiting enzyme, but the improvement of the feedback inhibition effect of L-valine is still insufficient. Summary of the invention

[0005] The purpose of the present invention is to regulate and transform Escherichia coli K-12MG1655 by means of metabolic engineering, so that Escherichia coli K-12MG1655 can realize the de novo synthesis and accumulation of L-valine, thereby realizing the fermentation production of L-valine with glucose as a substrate, and relieving the feedback inhibition pathway, thereby increasing the yield, and having good prospects and production potential.

[0006] The present invention provides a method for constructing an engineered strain for producing L-valine, wherein any one or more of the following modifications (1) to (11) are performed on Escherichia coli:

[0007] (1) Enhance the activity of ilvBN, the gene for subunit I of acetolactate synthase;

[0008] (2) Enhance the activity of ilvGM, the gene for subunit II of acetolactate synthase;

[0009] (3) Enhance the activity of ilvIH, the gene for subunit III of acetolactate synthase;

[0010] (4) enhancing the activity of the dicarboxylate reductoisomerase gene ilvC;

[0011] (5) enhancing the activity of the dicarboxylate dehydratase gene ilvD;

[0012] (6) Enhance the activity of the branched-chain amino acid transaminase gene ilvE;

[0013] (7) Knockout of the valine-pyruvate aminotransferase gene avtA;

[0014] (8) Knockout of the branched-chain amino acid transporter gene brnQ;

[0015] (9) Knockout of the regulatory RNA gene gcvB;

[0016] (10) Enhance the activity of branched-chain amino acid transporter brnFE;

[0017] (11) Knockout the lactate dehydrogenase gene ldhA.

[0018] In a specific example, the method for constructing the L-valine engineering strain of the present invention is to carry out the transformations (1) to (11) on the basis of Escherichia coli.

[0019] In a specific example, the specific method for constructing an engineered strain for producing L-valine is as follows: based on Escherichia coli, the expression frame of the acetolactate synthase subunit I gene ilvBN is integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesizing strain Val 01; using Val 01 as the starting strain, the expression frame of the acetolactate synthase subunit II gene ilvGM is integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesizing strain Val 02; using Val 02 as the starting strain, the expression frame of the acetolactate synthase subunit III gene ilvIH is integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesizing strain Val 03; using Val 03 as the starting strain, the expression frame of the dicarboxylic acid reductoisomerase gene ilvC is integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesizing strain Val 04; using Val 05 as the starting strain, the expression frame of the dicarboxylic acid reductoisomerase gene ilvC is integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesizing strain Val 06; Using Val04 as the starting strain, the expression frame of the dicarboxylic acid dehydratase gene ilvD was integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesis strain Val 05; using Val05 as the starting strain, the expression frame of the branched-chain amino acid transaminase gene ilvE was integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesis strain Val 06; using Val 06 as the starting strain, the valine-pyruvate aminotransferase gene avtA was knocked out from the Escherichia coli genome to obtain the L-valine synthesis strain Val 07; using Val 07 as the starting strain, the branched-chain amino acid transporter gene brnQ was knocked out from the Escherichia coli genome to obtain the L-valine synthesis strain Val 08; using Val 08 as the starting strain, the regulatory RNA gene gcvB was knocked out from the Escherichia coli genome to obtain the target engineering strain Val 09; using Val 09 was used as the starting strain, and the expression frame of the branched-chain amino acid transporter brnFE was integrated into the Escherichia coli genome to obtain the target engineered strain Val 10; using Val 10 as the starting strain, the lactate dehydrogenase gene ldhA was knocked out from the Escherichia coli genome to obtain the target engineered strain Val 11.

[0020] The DNA sequence of the acetolactate synthase subunit I gene ilvBN of the present invention is shown in SEQ ID No.1; the DNA sequence of the acetolactate synthase subunit II gene ilvGM is shown in SEQ ID No.2; the DNA sequence of the acetolactate synthase subunit III gene ilvIH is shown in SEQ ID No.3; the DNA sequence of the dicarboxylic acid reductoisomerase gene ilvC is shown in SEQ ID No.4; the DNA sequence of the dicarboxylic acid dehydratase gene ilvD is shown in SEQ ID No.5; the DNA sequence of the branched-chain amino acid transaminase gene ilvE is shown in SEQ ID No.6; the original DNA sequence of the valine-pyruvate aminotransferase gene avtA is shown in SEQ ID No.7; the original DNA sequence of the branched-chain amino acid transporter gene brnQ is shown in SEQ ID No.8; the original DNA sequence of the regulatory RNA gene gcvB is shown in SEQ ID No.9; the original DNA sequence of the branched-chain amino acid transporter brnFE is shown in SEQ ID No.10; the original DNA sequence of the lactate dehydrogenase gene ldhA is shown in SEQ ID No.11.

[0021] The basic Escherichia coli strain of the present invention may be an Escherichia coli commonly used in the art. In a specific example, the basic Escherichia coli strain is Escherichia coli K12-MG1655, which is commercially available.

[0022] The present invention enhances gene expression so as to increase the expression of the corresponding gene in the microorganism. The enhanced expression can be carried out according to conventional methods in the art, such as by increasing the copy number of the gene or allele or by using a strong promoter to increase the expression of the gene or the activity of the protein; for example, if the gene expression frame is inserted, it can be carried out according to conventional methods in the art, such as by CRISPR / Cas9 editing technology for gene integration expression, and the plasmids, vectors, etc. used can be plasmids, vectors commonly used in the art, such as pTarget plasmids, etc.

[0023] Knocking out a gene in the present invention means that the enzyme activity obtained by gene expression is reduced or inactivated, or the encoded enzyme is not expressed. The gene can be knocked out according to conventional methods in the art, such as by CRISPR / Cpf1 editing technology, and the plasmids and vectors used can be plasmids and vectors commonly used in the art, such as pcrEG plasmids, etc.

[0024] In one example, the promoter P can be integrated into the expression frame of the acetolactate synthase subunit I gene ilvBN, the acetolactate synthase subunit II gene ilvGM, and the acetolactate synthase subunit III gene ilvIH. tac , the promoter Ptac The sequence is shown in SEQ ID No. 12, and the integration method is a conventional method in the art, such as integrating ilvBN with the promoter P tac Integration is performed to form a Ptac-ilvBN expression cassette to control the expression of genes in the L-valine synthesis pathway. The promoter Ptac is an artificially constructed hybrid constitutive promoter, and the promoter and the target gene are connected using fusion PCR, and the specific method is the existing technology.

[0025] The invention also provides application of the engineering strain in producing L-valine.

[0026] The invention also provides application of the engineered strain in preparing food, feed or medicine containing L-valine.

[0027] The application of the present invention is specifically to ferment and culture the engineered strain of the present invention, collect the fermentation liquid, and obtain L-valine.

[0028] In some embodiments, the fermentation culture method of the engineered strain described in the present invention is: after the engineered strain is activated in LB medium, it is inoculated into a liquid seed medium to form a seed liquid, the seed liquid is transferred to a fermentation medium for culture, and the fermentation liquid is collected to obtain L-valine; preferably, the culture conditions in the liquid seed liquid are 35-37°C and 200-250rpm for 8-12h; preferably, the culture conditions of the fermentation medium are 35-37°C and 200-250rpm for 2-5 days.

[0029] In some embodiments, the components of the seed culture medium are: peptone 10 g / L, yeast powder 5 g / L, and NaCl 10 g / L.

[0030] In some embodiments, the fermentation medium components are: 40 g / L glucose, 2 g / L yeast powder, 2 g / L sodium citrate dihydrate, 0.6 g / L K2HPO4·3H2O, 16 g / L (NH4)2SO4, 30 g / L CaCO3, 0.005 g / L MnSO4·H2O, and 0.005 g / L FeSO4·7H2O.

[0031] Beneficial effects of the present invention:

[0032] (1) The engineered strain for producing L-valine provided by the present invention can realize the production of L-valine by fermentation using glucose as a substrate, by originally deleting the regulatory RNA gene gcvB and using a strong constitutive promoter P tacReplacing the original promoter of the three subunits of endogenous acetolactate synthase can more thoroughly remove the inhibition of endogenous acetolactate synthase at the translation level, and basically remove the feedback inhibition of L-valine, so that L-valine can be produced by fermentation with glucose as a substrate, achieving the effects of complete removal of feedback inhibition, sufficient enhancement of pathway genes, complete knockout of decomposition pathways, weakened decomposition product capacity and efficient product transport system.

[0033] (2) The recombinant Escherichia coli provided by the present invention is simple to construct and easy to use. During production, the product can be secreted autonomously and efficiently outside the cell without any other amino acid by-products, which lays a good foundation for the downstream separation and purification steps and has good prospects and production potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 This is a diagram of the synthesis pathway of L-valine in recombinant Escherichia coli;

[0035] Figure 2 This is a schematic diagram of constructing recombinant Escherichia coli.

[0036] Figure 3 This is a schematic diagram of the function of the regulatory gene gcvB. DETAILED DESCRIPTION

[0037] The following examples are provided for better understanding of the present invention, but are not intended to limit the present invention. The experimental methods in the following examples are conventional methods unless otherwise specified. The experimental materials used in the following examples are purchased from conventional biochemical reagent stores unless otherwise specified.

[0038] If not otherwise specified, the basic Escherichia coli strain used in the following examples is Escherichia coli K-12MG1655, purchased from Shanghai Biotechnology Collection Center (SHBCC), product number: SHBCC D24975.

[0039] Unless otherwise specified, the sample processing methods involved in the following examples are as follows:

[0040] The fermentation broth was collected and centrifuged at 14000 rpm at 20°C for 10 min. The supernatant was collected and filtered through a 0.22 μm water filter membrane before being added to a liquid phase detection bottle. The concentration of extracellular L-valine was detected by HPLC.

[0041] Unless otherwise specified, the detection methods involved in the following embodiments are as follows:

[0042] The L-valine synthesized by the recombinant Escherichia coli of the present invention is detected by a high performance liquid chromatography (HPLC) system (Agilent Technologies 1260 series), and the concentration of L-valine in the fermentation broth is determined by an InfinityLab Poroshell 120EC-C18 column (Agilent). The HPLC detector is an ultraviolet absorption detector (UV), and the detection temperature of the chromatographic column is set to 40°C. The sample needs to be pre-column derivatized with OPA boric acid before detection, and the preparation method of the pre-column derivatization reagent is as follows:

[0043] Boric acid solution: prepare 0.4 M boric acid solution and adjust the pH to 10.2 with NaOH.

[0044] OPA solution: Take 9 ml of the above 0.4 M boric acid solution and add 100 mg of o-phthalaldehyde, 1 mL of acetonitrile, and 100 μL of mercaptopropionic acid.

[0045] During pre-column derivatization, 7 μL of boric acid was extracted and mixed with 1 μL of sample, and then 2 μL of OPA solution was added, followed by 30 μL of water, and 20 μL was injected.

[0046] Mobile phase A: Dissolve 3.01 g of anhydrous sodium acetate in deionized water and dilute to 1 L, then add 200 μL of triethylamine and adjust the pH to 7.20±0.05 with 5% acetic acid; add 5 mL of tetrahydrofuran after filtration, mix and set aside.

[0047] Mobile phase B: Dissolve 3.01g of anhydrous sodium acetate in deionized water and dilute to 200mL; adjust the pH to 7.20±0.05 with 5% acetic acid; add 400mL of acetonitrile and 400mL of methanol to the solution after filtration, mix and set aside. Gradient elution. The detection flow rate is 0.8mL / min.

[0048] Unless otherwise specified, the primer information used in the following examples is shown in Table 1:

[0049] Table 1 Primer sequences

[0050]

[0051]

[0052]

[0053]

[0054] If not otherwise specified, the DNA sequence of the acetolactate synthase subunit I gene ilvBN described in the following examples is shown in SEQ ID No.1; the DNA sequence of the acetolactate synthase subunit II gene ilvGM is shown in SEQ ID No.2; the DNA sequence of the acetolactate synthase subunit III gene ilvIH is shown in SEQ ID No.3; the DNA sequence of the dicarboxylic acid reductoisomerase gene ilvC is shown in SEQ ID No.4; the DNA sequence of the dicarboxylic acid dehydratase gene ilvD is shown in SEQ ID No.5; the DNA sequence of the branched-chain amino acid transaminase gene ilvE is shown in SEQ ID No.6; the original DNA sequence of the valine-pyruvate aminotransferase gene avtA is shown in SEQ ID No.7; the original DNA sequence of the branched-chain amino acid transporter gene brnQ is shown in SEQ ID No.8; the original DNA sequence of the regulatory RNA gene gcvB is shown in SEQ ID No.9; the DNA sequence of the branched-chain amino acid transporter gene brnFE is shown in SEQ ID No.10; the DNA sequence of the lactate dehydrogenase gene ldhA is shown in SEQ ID No.11.

[0055] Example 1 Construction of strain Val 01

[0056] Starting from Escherichia coli K12-MG1655 (purchased from Shanghai Collection Biotechnology Center (SHBCC), product number: SHBCCD24975), the acetolactate synthase subunit I gene from Escherichia coli was integrated into the downstream region of the gene thrW site using the homologous recombination method. The specific steps are as follows:

[0057] In the first step, using the pTarget plasmid as a template, primers pTarget-thrW-F / pTarget-thrW-R were used to amplify a 2095 bp pTarget plasmid (SEQ ID NO. 13) fragment for constructing pTarget-thrW.

[0058] The amplification system was: PrimeSTAR Max DNA Polmerase 25 μL, DNA template 200 ng, primers (10 μM) 1 μL each, distilled water 23 μL, and the total volume was 50 μL.

[0059] Amplification conditions were as follows: pre-denaturation at 98°C for 5 minutes (1 cycle); denaturation at 98°C for 10 seconds, annealing at 55°C for 15 seconds, extension at 72°C for 1 minute (34 cycles); extension at 72°C for 5 minutes (1 cycle).

[0060] The amplified fragment was chemically transformed into DH5α competent cells (Takara-E.coli DH5α Competent Cells purchased from Bio-Rad Biotechnology (Beijing) Co., Ltd., product number: 9057), streaked onto LB solid medium containing spectinomycin (final concentration 1mM), and cultured overnight in a 37°C incubator. A single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1mM), and cultured overnight in a 37°C constant temperature shaker. The plasmid pTarget-thrW was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0061] The 574bp thrW-upstream fragment was amplified using primers thrW-up-F / thrW-up-R with K12-MG1655 as template; the 544bp thrW-downstream fragment was amplified using primers thrW-down-F / thrW-dwon-R with K12-MG1655 as template; the 1983bp thrW-ilvBN fragment was amplified using primers thrW-ilvBN-F / thrW-ilvBN-R with K12-MG1655 as template. The three fragments were fused and assembled using the fusion PCR method.

[0062] The fusion system is: PrimeSTAR Max DNA Polmerase 10μL, and the other three fragments are mixed in equal amounts to reach 10μL, with a total volume of 20μL.

[0063] The fusion conditions were as follows: pre-denaturation at 98°C for 5 minutes (1 cycle); denaturation at 98°C for 10 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 1 minute (20 cycles); and extension at 72°C for 5 minutes (1 cycle).

[0064] The Cpf1 plasmid was transformed into E. coli K12-MG1655 by chemical transformation. The pTarget-thrW plasmid and thrW-ilvBN DNA fragment were then transformed into E. coli K12-MG1655 containing Cpf1 by electroporation.

[0065] The transformation conditions are as follows: E. coli K12-MG1655 competent cells were prepared using the Competent Cell Preparation Kit, and the Cpf1 plasmid was transformed into E. coli K12-MG1655 by chemical transformation. Then, K12-MG1655 competent cells containing Cpf1 were prepared by electroporation. The pTarget-thrW plasmid and the thrW-ilvBN DNA fragment were transformed into the E. coli K12-MG1655 competent cells containing the Cpf1 plasmid by electroporation.

[0066] The electroporation conditions were as follows: first, prepare the competent cells of E. coli K12-MG1655 with Cpf1 plasmid for electroporation; place 50 μL competent cells on ice, add 500 ng pTarget-thrW plasmid and 1400 ng thrW-ilvBN DNA fragment, place on ice for 30 minutes, and transfer to a 0.1 cm Bio-Rad electroporation cup. Use MicroPulse (Bio-Rad) electroporator with an electrode parameter of 1.8 kV. After electroporation, quickly transfer 1 mL of LB culture medium to the electroporation cup, pipette 5 times, and then transfer to an EP tube, incubate at 220 rpm and 37°C for 2 hours.

[0067] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-thrW-F / test-thrW-R, the correct colony amplification product is a 3314 bp fragment, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture at 37°C, 220rpm for 10-12h to eliminate plasmid pTarget-ilvBN. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot plate them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-thrW-F / test-thrW-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 01.

[0068] Example 2 Construction of strain Val 02

[0069] Starting from strain Val 01, the acetolactate synthase subunit II gene from Escherichia coli was integrated into the downstream region of the gene ileY site by homologous recombination. The specific steps are as follows:

[0070] In the first step, using the pTarget plasmid as a template, primers pTarget-ileY-F / pTarget-ileY-R were used to amplify a 2095 bp fragment of the pTarget plasmid (preserved in our laboratory) for the construction of pTarget-ileY.

[0071] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0072] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-ileY was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0073] Primers ileY-up-F / ileY-up-R were used to amplify the 423bp ileY-upstream fragment with K12-MG1655 as template; primers ileY-down-F / ileY-dwon-R were used to amplify the 708bp ileY-downstream fragment with K12-MG1655 as template; primers ileY-ilvGM-F / ileY-ilvGM-R were used to amplify the 1977bp ileY-ilvGM fragment with K12-MG1655 as template. The three fragments were fused and assembled using the fusion PCR method.

[0074] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0075] The Cpf1 plasmid was transformed into Val 01 by chemical transformation. The pTarget-ileY plasmid and ileY-ilvGM DNA fragment were then transformed into Val 01 containing Cpf1 by electroporation.

[0076] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0077] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration is 1 mM) and kanamycin (final concentration is 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-ileY-F / test-ileY-R, the correct colony amplification product is a fragment of 3335 bp, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate the plasmid pTarget-ilvGM. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration is 1 mM) and kanamycin (final concentration is 1 mM) to verify that pTarget is successfully eliminated. And use primers test-ileY-F / test-ileY-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 02.

[0078] Example 3 Construction of strain Val 03

[0079] Starting from strain Val 02, the acetolactate synthase subunit III gene from Escherichia coli was integrated into the downstream region of the gene ypjC site by homologous recombination. The specific steps are as follows:

[0080] In the first step, using the pTarget plasmid as a template, primers pTarget-ypjC-F / pTarget-ypjC-R were used to amplify a 2095 bp fragment of the pTarget plasmid (stored in our laboratory) for the construction of pTarget-ypjC.

[0081] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0082] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-ypjC was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0083] Primers ypjC-up-F / ypjC-up-R were used to amplify the 557bp ypjC-upstream fragment with K12-MG1655 as template; primers ypjC-down-F / ypjC-dwon-R were used to amplify the 514bp ypjC-downstream fragment with K12-MG1655 as template; primers ypjC-ilvIH-F / ypjC-ilvIH-R were used to amplify the 2289bp ypjC-ilvIH fragment with K12-MG1655 as template. The three fragments were fused and assembled by fusion PCR.

[0084] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0085] The Cpf1 plasmid was transformed into Val 02 by chemical transformation. The pTarget-ypjC plasmid and ypjC-ilvIH DNA fragment were then transformed into Val 02 containing Cpf1 by electroporation.

[0086] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0087] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-ypjC-F / test-ypjC-R, the correct colony amplification product is a fragment of 3235 bp, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate plasmid pTarget-ilvIH. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot plate them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-ypjC-F / test-ypjC-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 03.

[0088] Example 4 Construction of strain Val 04

[0089] Starting from strain Val 03, the dicarboxylate reductoisomerase gene from Escherichia coli was integrated into the downstream region of the gene ycgH site by homologous recombination. The specific steps are as follows:

[0090] In the first step, using the pTarget plasmid as a template, primers pTarget-ycgH-F / pTarget-ycgH-R were used to amplify a 2095 bp fragment of the pTarget plasmid (preserved in this laboratory) for the construction of pTarget-ycgH.

[0091] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0092] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-ycgH was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0093] Primers ycgH-up-F / ycgH-up-R were used with K12-MG1655 as template to amplify a 530bp ycgH-upstream fragment; primers ycgH-down-F / ycgH-dwon-R were used with K12-MG1655 as template to amplify a 576bp ycgH-downstream fragment; primers ycgH-ilvC-F / ycgH-ilvC-R were used with K12-MG1655 as template to amplify a 1550bp ycgH-ilvC fragment. The three fragments were fused and assembled using the fusion PCR method.

[0094] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0095] The Cpf1 plasmid was transformed into Val 03 by chemical transformation. The pTarget-ycgH plasmid and ycgH-ilvC DNA fragment were then transformed into Val 03 containing Cpf1 by electroporation.

[0096] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0097] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-ycgH-F / test-ycgH-R, the correct colony amplification product is a 2896 bp fragment, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture at 37°C, 220rpm for 10-12h to eliminate plasmid pTarget-ilvC. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-ycgH-F / test-ycgH-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 04.

[0098] Example 5 Construction of strain Val 05

[0099] Starting from strain Val 04, the dicarboxylate dehydratase gene from Escherichia coli was integrated into the downstream region of the gene ycjV site by homologous recombination. The specific steps are as follows:

[0100] In the first step, using the pTarget plasmid as a template, primers pTarget-ycjV-F / pTarget-ycjV-R were used to amplify a 2095 bp fragment of the pTarget plasmid (preserved in this laboratory) for the construction of pTarget-ycjV.

[0101] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0102] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-ycjV was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0103] Primers ycjV-up-F / ycjV-up-R were used to amplify the 575bp ycjV-upstream fragment with K12-MG1655 as template; primers ycjV-down-F / ycjV-dwon-R were used to amplify the 540bp ycjV-downstream fragment with K12-MG1655 as template; primers ycjV-ilvD-F / ycjV-ilvD-R were used to amplify the 1917bp ycjV-ilvD fragment with K12-MG1655 as template. The three fragments were fused and assembled using the fusion PCR method.

[0104] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0105] The Cpf1 plasmid was transformed into Val 04 by chemical transformation. The pTarget-ycjV plasmid and ycjV-ilvD DNA fragment were then transformed into Val 04 containing Cpf1 by electroporation.

[0106] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0107] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-ycjV-F / test-ycjV-R, the correct colony amplification product is a fragment of 3426 bp, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate plasmid pTarget-ilvD. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-ycjV-F / test-ycjV-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 05.

[0108] Example 6 Construction of strain Val 06

[0109] Starting from strain Val 05, the branched-chain amino acid transaminase gene from Escherichia coli was integrated into the downstream region of the gene yeeP site by homologous recombination. The specific steps are as follows:

[0110] In the first step, using the pTarget plasmid as a template, primers pTarget-yeeP-F / pTarget-yeeP-R were used to amplify a 2095 bp fragment of the pTarget plasmid (preserved in our laboratory) for the construction of pTarget-yeeP.

[0111] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0112] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-yeeP was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0113] The primers yeeP-up-F / yeeP-up-R were used to amplify the 537bp yeeP-upstream fragment with K12-MG1655 as the template; the primers yeeP-down-F / yeeP-dwon-R were used to amplify the 539bp yeeP-downstream fragment with K12-MG1655 as the template; the primers yeeP-ilvE-F / yeeP-ilvE-R were used to amplify the 2918bp yeeP-ilvE fragment with K12-MG1655 as the template. The three fragments were fused and assembled by fusion PCR.

[0114] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0115] The Cpf1 plasmid was transformed into Val 05 by chemical transformation. The pTarget-yeeP plasmid and yeeP-ilvE DNA fragment were then transformed into Val 05 containing Cpf1 by electroporation.

[0116] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0117] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-yeeP-F / test-yeeP-R, the correct colony amplification product is a 4265 bp fragment, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture at 37°C, 220rpm for 10-12h to eliminate plasmid pTarget-ilvE. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot plate them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-yeeP-F / test-yeeP-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 06.

[0118] Example 7 Construction of strain Val 07

[0119] The valine-pyruvate aminotransferase gene avtA from Escherichia coli was knocked out by homologous recombination. The specific steps are as follows:

[0120] The first step is to design crRNA primers according to the PAM of the pEcCas9 protein: crRNA-avtA-F / crRNA-avtA-R. Pipette 10 μL of each of the two primers and mix them, and use annealing to construct the double-stranded DNA fragment crRAN-avtA.

[0121] The annealing conditions were as follows: 10 μL of each of the two primers crRNA-avtA-F / crRNA-avtA-R were mixed, denatured at 98°C for 2 minutes, and kept at 4°C for 2 minutes (the temperature change rate during this period was 0.1°C / s).

[0122] Using the pcrEG plasmid (SEQ ID NO. 14 in this invention) as a template, primers pcrEG-F / pcrEG-R were used to amplify a 3503 bp pcrEG linear plasmid fragment for constructing pcrEG-avtA.

[0123] The annealed crRNA-avtA was diluted 10 times, and crRNA-avtA and the pcrEG linear plasmid fragment were connected using T4 ligase.

[0124] T4 ligase ligation system: distilled water 6μL, diluted crRNA-avtA 1μL, pcrEG linear plasmid fragment 1μL, T4 Buffer 1μL, T4 DNALigase 1μL.

[0125] T4 ligase ligation conditions: incubation at 22°C for 3 hours.

[0126] The connected fragments were transferred to DH5α competent medium. After overnight culture at 37°C, a single colony was selected for PCR verification using primers test-pcrEG-F / test-pcrEG-R. The correct colony amplification product was a 1132bp fragment. A correct single colony was selected as a template and amplified using avtA-other-F / avtA-other-R. The correct colony amplification product was a 2267bp fragment. Using primers avtA-up-F / avtA-up-R and template K12-MG1655, the colony amplification product was a 522 fragment. Using primers avtA-down-F / avtA-down-R and template K12-MG1655, the colony amplification product was a 556 fragment. The three fragments were fused using the fusion PCR method. The pcrEG-avtA plasmid was obtained.

[0127] The amplification system was: PrimeSTAR Max DNA Polmerase 25 μL, DNA template 200 ng, primers (10 μM) 1 μL each, distilled water 23 μL, and the total volume was 50 μL.

[0128] Amplification conditions were as follows: pre-denaturation at 98°C for 5 minutes (1 cycle); denaturation at 98°C for 10 seconds, annealing at 55°C for 15 seconds, extension at 72°C for 1 minute (34 cycles); extension at 72°C for 5 minutes (1 cycle).

[0129] The fusion system is: PrimeSTAR Max DNA Polmerase 10μL, and the other three fragments are mixed in equal amounts to reach 10μL, with a total volume of 20μL.

[0130] The fusion conditions were as follows: pre-denaturation at 98°C for 5 minutes (1 cycle); denaturation at 98°C for 10 seconds, annealing at 60°C for 15 seconds, and extension at 72°C for 1 minute (20 cycles); and extension at 72°C for 5 minutes (1 cycle).

[0131] The fused plasmid was chemically transformed into DH5α competent medium, cultured overnight at 37°C, and then a single colony was picked and inoculated into LB liquid culture medium containing spectinomycin (final concentration 1mM), cultured overnight at 37°C, and the plasmid pcrEG-avtA was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0132] The pEcCas9 plasmid was transformed into Val 06 by chemical transformation. The pcrEG-avtA plasmid fragment was then transformed into Val 06 containing the pEcCas9 plasmid by chemical transformation.

[0133] The transformation conditions are as follows: Val 06 competent cells were prepared using the Competent Cell Preparation Kit, and the pEcCas9 plasmid was transformed into Val 06 by chemical transformation. Then, Val 06 competent cells containing pEcCas9 were prepared. The pcrEG-avtA plasmid was transformed into the Val 06 electroporation competent cells containing the pEcCas9 plasmid by chemical transformation.

[0134] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-avtA-F / test-avtA-R, the correct colony amplification product is a fragment of 1136 bp, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate the plasmid pcrEG-avtA. For the strains to be eliminated from the pcrEG-avtA plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that the pcrEG plasmid is successfully eliminated. And use primers test-avtA-F / test-avtA-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid pEcCas9. The strains to be eliminated from the pEcCas9 plasmid were picked and plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of pEcCas9. The recombinant E. coli with completed gene editing was obtained and named Val 07.

[0135] Example 8 Construction of strain Val 08

[0136] The branched-chain amino acid transporter gene brnQ from Escherichia coli was knocked out by homologous recombination. The specific steps are as follows:

[0137] The first step is to design the crRNA primer according to the PAM of the pEcCas9 protein:

[0138] crRNA-brnQ-F / crRNA-brnQ-R. Pipette 10 μL of each of the two primers and mix them, and use annealing to construct a double-stranded DNA fragment crRNA-brnQ.

[0139] Annealing conditions were the same as those used for avtA gene deletion described in Example 7.

[0140] Using the pcrEG plasmid as a template, primers pcrEG-F / pcrEG-R were used to amplify a 3503 bp pcrEG linear plasmid fragment for the construction of pcrEG-brnQ.

[0141] The annealed crRNA-brnQ was diluted 10 times, and crRNA-brnQ and pcrEG linear plasmid fragments were connected using T4 ligase.

[0142] The T4 ligase ligation system and ligation conditions were the same as those described in Example 7 for the method for deleting the avtA gene.

[0143] The connected fragments were transferred to DH5α competent medium. After overnight culture at 37°C, a single colony was picked for PCR verification using primers test-pcrEG-F / test-pcrEG-R. The correct colony amplification product was a 1354bp fragment. A correct single colony was selected as a template and amplified using brnQ-other-F / brnQ-other-R. The correct colony amplification product was a 2267bp fragment. Using primers brnQ-up-F / brnQ-up-R, the template was K12-MG1655, and the colony amplification product was a 536 fragment. Using primers brnQ-down-F / brnQ-down-R, the template was K12-MG1655, and the colony amplification product was a 545 fragment. The three fragments were fused using the fusion PCR method. The pcrEG-brnQ plasmid was obtained.

[0144] The amplification system and amplification conditions were the same as those used for the method for deleting the avtA gene described in Example 7.

[0145] The fusion system and fusion conditions were the same as those used for the avtA gene deletion method described in Example 7.

[0146] The fused plasmid was chemically transformed into DH5α competent medium, cultured overnight at 37°C, and then a single colony was picked and inoculated into LB liquid culture medium containing spectinomycin (final concentration 1mM), cultured overnight at 37°C, and the plasmid pcrEG-brnQ was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0147] The pEcCas9 plasmid was transformed into Val 07 by chemical transformation. The pcrEG-brnQ plasmid fragment was then transformed into Val 07 containing the pEcCas9 plasmid by chemical transformation.

[0148] The transformation conditions were the same as those used for avtA gene deletion described in Example 7.

[0149] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-brnQ-F / test-brnQ-R, the correct colony amplification product is a 1345 bp fragment, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture at 37°C and 220rpm for 10-12h to eliminate the plasmid pcrEG-brnQ. For the strains to be eliminated from the pcrEG-brnQ plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that the pcrEG plasmid is successfully eliminated. And use primers test-brnQ-F / test-brnQ-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid pEcCas9. The strains to be eliminated from the pEcCas9 plasmid were picked and plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of pEcCas9. The recombinant E. coli with completed gene editing was obtained and named Val 08.

[0150] Example 9 Construction of strain Val 09

[0151] The regulatory RNA gene gcvB from Escherichia coli was knocked out by homologous recombination. The specific steps are as follows:

[0152] The first step is to design the crRNA primer according to the PAM of the pEcCas9 protein:

[0153] crRNA-gcvB-F / crRNA-gcvB-R. Pipette 10 μL of each of the two primers and mix them, and use annealing to construct a double-stranded DNA fragment crRNA-gcvB.

[0154] Annealing conditions were the same as those used for avtA gene deletion described in Example 7.

[0155] Using the pcrEG plasmid as a template, primers pcrEG-F / pcrEG-R were used to amplify a 3503 bp pcrEG linear plasmid fragment for the construction of pcrEG-gcvB.

[0156] The annealed crRNA-gcvB was diluted 10 times, and crRNA-gcvB and pcrEG linear plasmid fragments were connected using T4 ligase.

[0157] The T4 ligase ligation system and ligation conditions were the same as those described in Example 7 for the method for deleting the avtA gene.

[0158] The connected fragments were transferred to DH5α competent medium. After overnight culture at 37°C, a single colony was selected for PCR verification using primers test-pcrEG-F / test-pcrEG-R. The correct colony amplification product was a 1356bp fragment. A correct single colony was selected as a template and amplified using gcvB-other-F / gcvB-other-R. The correct colony amplification product was a 2267bp fragment. Using primers gcvB-up-F / gcvB-up-R, the template was K12-MG1655, and the colony amplification product was a 587 fragment. Using primers gcvB-down-F / gcvB-down-R, the template was K12-MG1655, and the colony amplification product was a 595 fragment. The three fragments were fused using the fusion PCR method. The pcrEG-gcvB plasmid was obtained.

[0159] The amplification system and amplification conditions were the same as those used for the method for deleting the avtA gene described in Example 7.

[0160] The fusion system and fusion conditions were the same as those used for the avtA gene deletion method described in Example 7.

[0161] The fused plasmid was chemically transformed into DH5α competent medium, cultured overnight at 37°C, and then a single colony was picked and inoculated into LB liquid culture medium containing spectinomycin (final concentration 1mM), cultured overnight at 37°C, and the plasmid pcrEG-gcvB was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0162] The pEcCas9 plasmid was transformed into Val 08 by chemical transformation. The pcrEG-gcvB plasmid fragment was then transformed into Val 08 containing the pEcCas9 plasmid by chemical transformation. The action diagram of the gene gcvB is shown in Figure 3 shown.

[0163] The transformation conditions were the same as those used for avtA gene deletion described in Example 7.

[0164] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration is 1 mM) and kanamycin (final concentration is 1 mM), culture it at 37℃ overnight, and select single colonies for PCR verification. The primers used are

[0165] test-gcvB-F / test-gcvB-R, the correct colony amplification product is a 1356bp fragment. Select a correct single colony and inoculate the correct single colony into a liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate the plasmid pcrEG-gcvB. Pick single clones from the strains to be eliminated from the pcrEG-gcvB plasmid and spot them on solid LB medium containing spectinomycin (final concentration of 1mM) and kanamycin (final concentration of 1mM) to verify the successful elimination of the pcrEG plasmid. And use primers test-gcvB-F / test-gcvB-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid pEcCas9. The strains to be eliminated from the pEcCas9 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of pEcCas9. The recombinant E. coli with completed gene editing was obtained and named Val 09.

[0166] Example 10 Construction of strain Val 10

[0167] Starting from strain Val 09, the branched-chain amino transporter gene of Corynebacterium glutamicum was integrated into the downstream region of the gene nhaR site by homologous recombination. The specific steps are as follows:

[0168] In the first step, using the pTarget plasmid as a template, primers pTarget-nhaR-F / pTarget-nhaR-R were used to amplify a 2095 bp fragment of the pTarget plasmid (stored in our laboratory) for the construction of pTarget-nhaR.

[0169] The amplification system and amplification conditions were the same as those used for the ilvBN gene insertion method described in Example 1.

[0170] The amplified fragment was chemically transformed into DH5α competent medium, streaked onto LB solid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C incubator, and then a single colony was picked and inoculated into LB liquid medium containing spectinomycin (final concentration 1 mM), cultured overnight in a 37°C constant temperature shaker, and the plasmid pTarget-nhaR was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0171] Primers nhaR-up-F / nhaR-up-R were used to amplify the 577bp nhaR-upstream fragment with K12-MG1655 as template; primers nhaR-down-F / nhaR-dwon-R were used to amplify the 586bp nhaR-downstream fragment with K12-MG1655 as template; primers nhaR-brnFE-F / nhaR-brnFE-R were used to amplify the 1147bp nhaR-brnFE fragment with K12-MG1655 as template. The three fragments were fused and assembled by fusion PCR.

[0172] The fusion system and fusion conditions were the same as those used for ilvBN gene insertion described in Example 1.

[0173] The Cpf1 plasmid was transformed into Val 09 by chemical transformation. The pTarget-nhaR plasmid and nhaR-brnFE DNA fragment were then transformed into Val 09 containing Cpf1 by electroporation.

[0174] The conditions for chemical transformation and electroporation were the same as those used for ilvBN gene insertion described in Example 1.

[0175] Take 200 μL of bacterial solution and apply it on LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select single colonies for PCR verification, use primers test-nhaR-F / test-nhaR-R, the correct colony amplification product is a fragment of 3975 bp, select a correct single colony, inoculate the correct single colony into liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate plasmid pTarget-brnFE. For the strains to be eliminated from the pTarget plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that pTarget is successfully eliminated. And use primers test-nhaR-F / test-nhaR-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5g / L glucose and 10g / L sucrose, and cultured at 37°C for 10-12h to eliminate the plasmid Cpf1. The strains to be eliminated from the Cpf1 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of Cpf1. The recombinant E. coli with completed gene editing was obtained and named Val 10.

[0176] Example 11 Construction of target strain Val 11

[0177] The lactate dehydrogenase gene ldhA from Escherichia coli was knocked out by homologous recombination. The specific steps are as follows:

[0178] The first step is to design crRNA primers according to the PAM of the pEcCas9 protein: crRNA-ldhA-F / crRNA-ldhA-R. Pipette 10 μL of each of the two primers and mix them, and use annealing to construct the double-stranded DNA fragment crRAN-ldhA.

[0179] Annealing conditions were the same as those used for avtA gene deletion described in Example 7.

[0180] Using the pcrEG plasmid (stored in our laboratory) as a template, primers pcrEG-F / pcrEG-R were used to amplify a 3503 bp pcrEG linear plasmid fragment for the construction of pcrEG-ldhA.

[0181] The annealed crRNA-ldhA was diluted 10 times, and crRNA-ldhA and the pcrEG linear plasmid fragment were ligated using T4 ligase.

[0182] The T4 ligase ligation system and ligation conditions were the same as those described in Example 7 for the method for deleting the avtA gene.

[0183] The connected fragments were transferred to DH5α competent medium. After overnight culture at 37°C, a single colony was selected for PCR verification using primers test-pcrEG-F / test-pcrEG-R. The correct colony amplification product was a 1364bp fragment. A correct single colony was selected as a template and amplified using ldhA-other-F / ldhA-other-R. The correct colony amplification product was a 2267bp fragment. Using primers ldhA-up-F / ldhA-up-R and template K12-MG1655, the colony amplification product was a 575 fragment. Using primers ldhA-down-F / ldhA-down-R and template K12-MG1655, the colony amplification product was a 574 fragment. The three fragments were fused using the fusion PCR method. The pcrEG-ldhA plasmid was obtained.

[0184] The amplification system and amplification conditions were the same as those used for the method for deleting the avtA gene described in Example 7.

[0185] The fusion system and fusion conditions were the same as those used for the avtA gene deletion method described in Example 7.

[0186] The fused plasmid was chemically transformed into DH5α competent medium, cultured overnight at 37°C, and then a single colony was picked and inoculated into LB liquid culture medium containing spectinomycin (final concentration 1 mM), cultured overnight at 37°C, and the plasmid pcrEG-ldhA was extracted using the SanPrep column plasmid DNA small-scale extraction kit.

[0187] The pEcCas9 plasmid was transformed to Val 10 by chemical transformation. The pcrEG-ldhA plasmid fragment was then transformed to Val 10 containing the pEcCas9 plasmid by chemical transformation.

[0188] The transformation conditions were the same as those used for avtA gene deletion described in Example 7.

[0189] Take 200 μL of bacterial solution and apply it on an LB plate containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM), culture at 37°C overnight, select a single colony for PCR verification, the primers used are test-ldhA-F / test-ldhA-R, the correct colony amplification product is a 1364 bp fragment, select a correct single colony, inoculate the correct single colony into a liquid LB medium containing 2.5% (V / V) 1M L-rhamnose, and culture it at 37°C and 220rpm for 10-12h to eliminate the plasmid pcrEG-ldhA. For the strains to be eliminated from the pcrEG-ldhA plasmid, pick single clones and spot them on solid LB medium containing spectinomycin (final concentration of 1 mM) and kanamycin (final concentration of 1 mM) to verify that the pcrEG plasmid is successfully eliminated. And use primers test-ldhA-F / test-ldhA-R to pick single colonies for PCR verification. The correct single colony was inoculated onto a solid LB medium containing 5 g / L glucose and 10 g / L sucrose, and cultured at 37°C for 10-12 hours to eliminate the plasmid pEcCas9. The strains to be eliminated from the pEcCas9 plasmid were picked and single clones were plated onto solid LB medium containing kanamycin and no additional antibiotics to verify the successful elimination of pEcCas9. The recombinant E. coli that completed gene editing was obtained and named Val 11.

[0190] The specific construction flow chart and schematic diagram are as follows Figure 1 and Figure 2 shown.

[0191] Example 12 Production of L-valine by shake flask fermentation of recombinant Escherichia coli

[0192] The target engineered strain Val 11 obtained in the above Example 11 was activated in LB medium and inoculated into liquid seed medium. Seed medium (g / L): peptone 10, yeast powder 5, NaCl 10; culture conditions: culture at 37°C, 220rpm for 10h. Then the seed liquid was inoculated into the fermentation medium at an inoculation rate of 4%. Shake flask fermentation medium (g / L): glucose 40, yeast powder 2, sodium citrate dihydrate 2, K2HPO4·3H2O 0.6, (NH4)2SO4 16, CaCO330, trace elements: 0.005g / L MnSO4·H2O, 0.005g / L FeSO4·7H2O. ; culture conditions: 37°C, 220rpm, 72h.

[0193] At the end of fermentation, the L-valine concentration of the fermentation supernatant was determined by high performance liquid chromatography (HPLC). The fermentation broth was first centrifuged at 14000 rpm at 20°C for 10 min, and the supernatant was collected and the concentration of extracellular L-valine was detected by HPLC. The total amount of extracellular L-valine in the recombinant Escherichia coli was finally determined to be 21.3 g / L.

Claims

1. A method for constructing an engineered strain for producing L-valine, characterized in that: Based on E. coli, any one or more of the following modifications (1) to (11) are performed: (1) Enhance the activity of ilvBN, the gene for subunit I of acetolactate synthase; (2) Enhance the activity of ilvGM, the gene for subunit II of acetolactate synthase; (3) Enhance the activity of ilvIH, the gene for subunit III of acetolactate synthase; (4) enhancing the activity of the dicarboxylate reductoisomerase gene ilvC; (5) enhancing the activity of the dicarboxylate dehydratase gene ilvD; (6) Enhance the activity of the branched-chain amino acid transaminase gene ilvE; (7) Knockout of the valine-pyruvate aminotransferase gene avtA; (8) Knockout of the branched-chain amino acid transporter gene brnQ; (9) Knockout of the regulatory RNA gene gcvB; (10) Enhance the activity of branched-chain amino acid transporter brnFE; (11) Knockout the lactate dehydrogenase gene ldhA.

2. The method for constructing an L-valine engineering strain according to claim 1, wherein the transformations (1) to (11) are performed on Escherichia coli.

3. A method for constructing an engineered strain for producing L-valine, characterized in that: On the basis of Escherichia coli, the expression frame of acetolactate synthase subunit I gene ilvBN was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 01; using Val 01 as the starting strain, the expression frame of acetolactate synthase subunit II gene ilvGM was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 02; using Val 02 as the starting strain, the expression frame of acetolactate synthase subunit III gene ilvIH was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 03; using Val 03 as the starting strain, the expression frame of dicarboxylic acid reductoisomerase gene ilvC was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 04; using Val 04 as the starting strain, the expression frame of dicarboxylic acid dehydratase gene ilvD was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 05; using Val 06 as the starting strain, the expression frame of dicarboxylic acid dehydratase gene ilvD was integrated and inserted into the Escherichia coli genome to obtain L-valine synthesis strain Val 07; Using Val 05 as the starting strain, the expression frame of the branched-chain amino acid transaminase gene ilvE was integrated and inserted into the Escherichia coli genome to obtain the L-valine synthesis strain Val 06; using Val 06 as the starting strain, the valine-pyruvate aminotransferase gene avtA was knocked out from the Escherichia coli genome to obtain the L-valine synthesis strain Val 07; using Val 07 as the starting strain, the branched-chain amino acid transporter gene brnQ was knocked out from the Escherichia coli genome to obtain the L-valine synthesis strain Val 08; using Val 08 as the starting strain, the regulatory RNA gene gcvB was knocked out from the Escherichia coli genome to obtain the target engineering strain Val 09; using Val 09 as the starting strain, the expression frame of the branched-chain amino acid transporter brnFE was integrated and inserted into the Escherichia coli genome to obtain the target engineering strain Val 10; using Val 10 as the starting strain, the lactate dehydrogenase gene ldhA was knocked out from the Escherichia coli genome to obtain the target engineering strain Val 11.

4. The method for constructing an engineered strain for producing L-valine according to any one of claims 1 to 3, characterized in that: The DNA sequence of the acetolactate synthase subunit I gene ilvBN is shown in SEQ ID No.1; the DNA sequence of the acetolactate synthase subunit II gene ilvGM is shown in SEQ ID No.2; the DNA sequence of the acetolactate synthase subunit III gene ilvIH is shown in SEQ ID No.3; the DNA sequence of the dicarboxylic acid reductoisomerase gene ilvC is shown in SEQ ID No.4; the DNA sequence of the dicarboxylic acid dehydratase gene ilvD is shown in SEQ ID No.5; the DNA sequence of the branched-chain amino acid transaminase gene ilvE is shown in SEQ ID No.6; the original DNA sequence of the valine-pyruvate aminotransferase gene avtA is shown in SEQ ID No.7; the original DNA sequence of the branched-chain amino acid transporter gene brnQ is shown in SEQ ID No.8; the original DNA sequence of the regulatory RNA gene gcvB is shown in SEQ ID No.9; the original DNA sequence of the branched-chain amino acid transporter brnFE is shown in SEQ ID No.10; the original DNA sequence of the lactate dehydrogenase gene ldhA is shown in SEQ ID No. As shown in IDNo.

11.

5. The method for constructing an engineered strain for producing L-valine according to any one of claims 1 to 3, characterized in that: The Escherichia coli is Escherichia coli K12-MG1655.

6. The method for constructing an engineered strain for producing L-valine according to any one of claims 1 to 3, characterized in that: The promoter P is integrated into the expression frame of the acetolactate synthase subunit I gene ilvBN, the acetolactate synthase subunit II gene ilvGM, and the acetolactate synthase subunit III gene ilvIH tac , the promoter P tac The sequence is shown as SEQ ID No.

12.

7. An engineered strain constructed by the construction method according to any one of claims 1 to 6.

8. Use of the engineered strain according to claim 7 in producing L-valine.

9. The use according to claim 8, characterized in that: Fermentation culture of the engineered strain according to any one of claims 1 to 6, collecting the fermentation broth, and obtaining L-valine; preferably, the fermentation culture method of the engineered strain is: after the engineered strain is activated in LB medium, inoculated into a liquid seed medium to form a seed liquid, the seed liquid is transferred to a fermentation medium for culture, and the fermentation broth is collected to obtain L-valine; preferably, the culture conditions in the liquid seed liquid are 35-37°C, 200-250rpm for 8-12h; preferably, the culture conditions of the fermentation medium are 35-37°C, 200-250rpm for 2-5 days; preferably, the seed medium components are: peptone 10g / L, yeast powder 5g / L, NaCl 10g / L; preferably, the fermentation medium components are: glucose 40g / L, yeast powder 2g / L, sodium citrate dihydrate 2g / L, K2HPO4·3H2O is 0.6g / L, (NH4)2SO4 is 16g / L, CaCO3 is 30g / L, MnSO4·H2O is 0.005g / L, and FeSO4·7H2O is 0.005g / L.

10. Use of the engineered strain according to claim 7 in the preparation of food, feed or medicine containing L-valine.

Citation Information

Cited By

  • Method for synthesizing L-valine from escherichia coli based on membrane-free organelle space regulation and control

    CN119930839A

  • Valine production strain as well as construction method and application thereof

    CN121737169A

  • Valine-producing strain and construction method and application thereof

    CN121737169B